| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000032284 |
| Receipt No. | R000036815 |
| Official scientific title of the study | Safety excessive intake study of drink-A containing lactic acid bacteria |
| Date of disclosure of the study information | 2018/04/23 |
| Last modified on | 2018/08/24 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | Safety excessive intake study of drink-A containing lactic acid bacteria | |
| Title of the study (Brief title) | Safety excessive intake study of drink-A containing lactic acid bacteria | |
| Region |
|
|
| Condition | ||
| Condition | Healthy adult | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Confirm the safety of the beverage containing Lactobacillus casei NY 1301 strain on healthy adults,3-fold quantity of recommended daily intake for 4 weeks. |
| Basic objectives2 | Safety |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Frequency of side effects |
| Key secondary outcomes | Frequency of adverse events, Physical examination, Blood test, Urinalysis, Background factors, Lifestyle background |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Intake of drink containing lactic acid bacteria for 4 weeks. (3-fold quantity of recommended daily intake) | |
| Interventions/Control_2 | Intake of placebo drink for 4 weeks.(3-fold quantity of recommended daily intake) | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1)Subjects from 20 to 69 years-old
2)Subjects undergoing none of medical treatments 3)Subjects who can record daily logs daily during the designated period 4)Subjects who can record daily logs during the designated period 5)Subjects who can record diet records on specified days |
|||
| Key exclusion criteria | 1)Subjects with serious liver disease,renal /heart disease,organ disorder,diabetes,foodallergy,gastrointestinal disease,other serious diseases
2)Subjects allergic to a specific drug or food 3)Subjects allergic to samples in this study 4)Pregnants,lactating women or who is going to be pregnant during study 5)Subjects drawn blood over 200mL last 1 month,or over 400mL last3 months before consent acquisition date 6)Subjects who can't maintain everyday life habits 7)Subjects with a several variation of the amount of diet or movement 8)Subjects drink alcohol over 500mL in terms of beer per day 9)Subjects smoke over average 20 cigarettes per day 10)Subjects who can not refrain from using health foods,during the study 11)Subjects who can not take the test food as instructed 12)Subjects who have participated in the other clinical studies 13)Subjects judged as unsuitable for the study by the principal investigator for other reasons |
|||
| Target sample size | 30 | |||
| Research contact person | |
| Name of lead principal investigator | Hiroshi Moriyama |
| Organization | Kanazawabunko Hospital |
| Division name | Vice president |
| Address | 2-6-22,Kamariyahigashi,Kanazawa-ku, Yokohama-shi,Kanagawa |
| TEL | 045-785-3311 |
| watanabe@kanabun-hp.jp | |
| Public contact | |
| Name of contact person | Natsumi Oka |
| Organization | APO PLUS STATION CO., LTD. |
| Division name | CRO Department Food Test Division |
| Address | 2-14-1,Nihonbashi,Chuo-ku,Tokyo |
| TEL | 03-6386-8809 |
| Homepage URL | |
| n2-oka@apoplus.co.jp | |
| Sponsor | |
| Institute | APO PLUS STATION CO., LTD. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Nissin York Co.,Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 金沢文庫病院(神奈川県)、ゆきクリニック(東京都)、戸田中央総合病院(埼玉県) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000036815 |